Related Experiment Video
Updated: May 16, 2026
07:42
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Aflibercept in lung cancer
Joel W Neal1, Heather A Wakelee
1Stanford University/Stanford Cancer Institute, Department of Medicine (Oncology), Stanford, CA, USA.
Expert Opinion on Biological Therapy
|December 4, 2012
Summary
Aflibercept, a VEGF inhibitor, showed efficacy in colorectal cancer but failed to improve outcomes in lung cancer clinical trials. Future research may identify biomarkers to guide anti-angiogenesis therapy selection.
Area of Science:
- Oncology
- Cancer Biology
- Vascular Biology
Background:
- Angiogenesis is crucial for solid tumor growth, mediated by vascular endothelial growth factor (VEGF).
- Bevacizumab (anti-VEGF-A antibody) improves survival in non-small-cell lung cancer (NSCLC) with chemotherapy.
- Aflibercept (VEGF Trap) targets VEGF-A, VEGF-B, and placental growth factor (PlGF) with higher affinity than bevacizumab.
Purpose of the Study:
- To review recent clinical trials on aflibercept for lung cancer treatment.
- To assess the efficacy and role of aflibercept in various lung cancer settings.
Main Methods:
- Literature review of published clinical trials.
- Inclusion of preliminary data presented at major scientific meetings.
Main Results:
- Aflibercept demonstrated Phase III efficacy in metastatic colorectal cancer.
- Large-scale clinical trials in lung cancer did not yield positive results for aflibercept.
Conclusions:
- Despite efficacy in other cancers, aflibercept has not proven beneficial in lung cancer trials.
- Biomarker identification is essential for selecting patients who may benefit from anti-angiogenesis therapies like aflibercept.
